Login / Signup

Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study.

Neeraj NarulaEmily C L WongJohn K MarshallVipul JairathParambir S DulaiWalter Reinisch
Published in: The American journal of gastroenterology (2022)
Patients with UC who achieve early PMS remission with vedolizumab have greater odds of week 52 remission compared with delayed responders.
Keyphrases
  • ulcerative colitis
  • patients with inflammatory bowel disease
  • rheumatoid arthritis
  • systemic lupus erythematosus
  • study protocol
  • placebo controlled